Myriad Genetics (MYGN) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$27.4 million.
- Myriad Genetics' Net Income towards Common Stockholders fell 2398.19% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 24525.86%. This contributed to the annual value of -$127.3 million for FY2024, which is 5165.21% up from last year.
- As of Q3 2025, Myriad Genetics' Net Income towards Common Stockholders stood at -$27.4 million, which was down 2398.19% from -$330.5 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' Net Income towards Common Stockholders ranged from a high of $24.6 million in Q3 2021 and a low of -$330.5 million during Q2 2025
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$31.2 million (2023), whereas its average is -$46.7 million.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 26184.21% in 2021, then tumbled by 80054.5% in 2025.
- Over the past 5 years, Myriad Genetics' Net Income towards Common Stockholders (Quarter) stood at -$7.6 million in 2021, then plummeted by 456.58% to -$42.3 million in 2022, then grew by 26.24% to -$31.2 million in 2023, then crashed by 36.22% to -$42.5 million in 2024, then skyrocketed by 35.53% to -$27.4 million in 2025.
- Its last three reported values are -$27.4 million in Q3 2025, -$330.5 million for Q2 2025, and -$100000.0 during Q1 2025.